A Study to Determine the Effect of Food on the Pharmacokinetics of Abiraterone Acetate in Healthy Male Patients

Inclusion Criteria:

• In good general health as determined by no clinically significant findings on medical history, physical examination, vital signs, 12-lead electrocardiogram, and clinical laboratory measurements
• Body mass index within 18 kg/m2 to 32 kg/m2, inclusive
• Non-tobacco users
• Clinical laboratory values within protocol-defined parameters
• Negative hepatitis panel (including hepatitis B surface antigen [HBsAg] and hepatitis C virus antibody [anti-HCV]),and negative human immunodeficiency virus (HIV) antibody screens
• Negative test for selected drugs of abuse
• Agrees to protocol-defined use of effective contraception

Exclusion Criteria:

• Significant history or manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological or psychiatric disorder, as determined by the Principal Investigator
• History or presence of an abnormal electrocardiogram
• History of stomach or intestinal surgery resection that would potentially alter absorption and/or excretion of orally administered drugs
• Screening serum total testosterone of <200 ng/dL
• History of hypersensitivity reaction to the study drug, related compounds or excipients used in the formulation
• Receipt of an investigational drug within 5 half-lives or 30 days prior to Day -1, whichever is longer
• Abnormal diet during the 30 days prior to Day 1
• Donation of blood or significant loss of blood within 56 days or plasma within 14 days prior to Day -1
• Planned donation of blood or plasma from Screening through Study Completion, Day 21
• Receipt of blood products within 2 months prior to Day 1
• History of protocol-defined alcohol abuse
• Known or suspected use of illicit drugs within the last year
• Use of any medication on a chronic basis
• Use of any prescription medications/products or over-the-counter non-prescription preparations within 5 half-lives or 7 days prior to Day -1 unless deemed acceptable by the Sponsor
• Consumption of alcohol-containing foods or beverages within 24 hours prior to the first Check-in (Day -1)
• Unwillingness to abstain from alcohol consumption from Day -1 to Study Completion (Day21)
• Consumption of caffeine-containing or grapefruit-containing foods or beverages within 72 hours prior to Day -1
• Unwillingness to abstain from caffeine-containing or grapefruit-containing foods or beverages from Day -1 through Study Completion (Day21)
• Presence of sexual dysfunction or any medical condition that would affect sexual function
• Unwillingness to refrain from strenuous exercise from 48 hours prior to Day -1 and for the duration of the study
• Presence of any condition that, in the opinion of the Investigator, would limit the participant's ability to complete and/or participate in this study
• Unwillingness to refrain from using any tobacco or nicotine-containing products during screening and throughout the study to Study Completion (Day 21)